pioglitazone has been researched along with Complication, Postoperative in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Excerpt | Relevance | Reference |
---|---|---|
"To examine the impact of a recent surgery on development of endometriosis-related adhesions in a chimeric model and to determine the therapeutic efficacy of pioglitazone (PIO)." | 3.77 | Development and prevention of postsurgical adhesions in a chimeric mouse model of experimental endometriosis. ( Bruner-Tran, KL; Camargos, AF; Carvalho-Macedo, AC; Crispens, MA; Herington, JL; Lebovic, DI; Osteen, KG, 2011) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Lo, C | 1 |
Toyama, T | 1 |
Oshima, M | 1 |
Jun, M | 1 |
Chin, KL | 1 |
Hawley, CM | 1 |
Zoungas, S | 1 |
Zhang, Z | 1 |
Yuan, H | 1 |
Zhao, H | 1 |
Qi, B | 1 |
Li, F | 1 |
An, L | 1 |
Herington, JL | 1 |
Crispens, MA | 1 |
Carvalho-Macedo, AC | 1 |
Camargos, AF | 1 |
Lebovic, DI | 1 |
Bruner-Tran, KL | 1 |
Osteen, KG | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Efficacy and Safety of Empagliflozin Compared With Linagliptin in New-onset Diabetes Mellitus After Kidney Transplantation[NCT03642184] | Phase 4 | 6 participants (Actual) | Interventional | 2018-07-14 | Terminated (stopped due to Difficult in enrolling suitable participants) | ||
Influence of Pioglitazone for Renal Transplant Function in Diabetics - a Double Blind Randomised Placebo Controlled Cross Over Study[NCT00507494] | Phase 3 | 0 participants | Interventional | 2007-07-31 | Completed | ||
Treat-To-Target Trial of Continuous Subcutaneous, Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation (SAPT-NODAT)[NCT01680185] | Phase 3 | 85 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
A Randomized Controlled Trial of Pioglitazone on Insulin Resistance, Insulin Secretion and Atherosclerosis in Renal Allograft Recipients Without History of Diabetes[NCT00598013] | 83 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
Vildagliptin in New Onset Diabetes After Transplantation - A Double-blind, Randomized, Placebo-controlled Trial[NCT00980356] | Phase 2 | 32 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
Intravenous Insulin Protocol in Diabetes and Renal Transplantation Study[NCT00609986] | 104 participants (Actual) | Interventional | 2007-07-31 | Completed | |||
The Effect of Sitagliptin Treatment on Glucose Metabolism and Endothelial Function in Renal Transplant Recipients - JANUVIA-08[NCT00740363] | Phase 4 | 25 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
Treat-to-target Trial of Basal Insulin in Post-transplant Hyperglycemia (TIP): Efficacy and Safety of a Novel Protocol in Renal Transplant Recipients Receiving a Tacrolimus-based Immunosuppression[NCT00830297] | Phase 2 | 50 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Post-transplantation Diabetes Mellitus[NCT03157414] | Phase 4 | 49 participants (Actual) | Interventional | 2016-11-07 | Completed | ||
Randomized Controlled Trial Comparing the Metabolic Efficiency of Allogeneic Pancreatic Islet Transplantation to Intensive Insulin Therapy for the Treatment of Type 1 Diabetes[NCT01148680] | Phase 3 | 50 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
Glucose Control in Pre-Diabetic Renal Transplant Patients: Efficacy and Safety of Vildagliptin and Pioglitazone[NCT01346254] | Phase 2 | 51 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
Randomized Study of the Impact of Peri-operative Glucose Control on Short Term Renal Allograft Function After Transplantation[NCT01643382] | 60 participants (Actual) | Interventional | 2012-08-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Grades IA through III and antibody immediate rejection, either A (immediate or hyperacute) or B (delayed or accelerated acute) were diagnosed and classified based on renal allograft biopsies according to the Banff 97 Working Classification of Renal Allograph Pathology. (NCT00609986)
Timeframe: 30 months
Intervention | participants (Number) |
---|---|
Intensive | 9 |
Control | 2 |
Need for dialysis in the first week post-transplant in a patient who required dialysis pre-transplantation or day-10 post-transplant creatinine concentration above 2.5 mg/dl. (NCT00609986)
Timeframe: 10 days
Intervention | participants (Number) |
---|---|
Intensive | 8 |
Control | 12 |
Blood glucose greater than 350 mg/dl. (NCT00609986)
Timeframe: 30 months
Intervention | participants (Number) |
---|---|
Intensive | 5 |
Control | 12 |
Blood glucose less than 40 mg/dl (NCT00609986)
Timeframe: 30 months
Intervention | participants (Number) |
---|---|
Intensive | 7 |
Control | 2 |
Our primary endpoint will be poor initial graft function defined by the occurrence of DGF (defined by a decrease in serum creatinine of <10%/day for 3 consecutive days after transplant) or slow graft function (serum creatinine >3 mg/dL 5 days after transplant without dialysis) (NCT01643382)
Timeframe: 7 days after transplant
Intervention | Participants (Count of Participants) |
---|---|
Tight Glucose Control | 13 |
Standard Glucose Control | 22 |
1 review available for pioglitazone and Complication, Postoperative
Article | Year |
---|---|
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2020 |
2 other studies available for pioglitazone and Complication, Postoperative
Article | Year |
---|---|
PPARĪ³ activation ameliorates postoperative cognitive decline probably through suppressing hippocampal neuroinflammation in aged mice.
Topics: Aging; Anilides; Animals; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cognitive Dysfunction; | 2017 |
Development and prevention of postsurgical adhesions in a chimeric mouse model of experimental endometriosis.
Topics: Animals; Disease Models, Animal; Endometriosis; Endometrium; Female; Humans; Mice; Mice, Nude; Piogl | 2011 |